Opinion: Semaglutide is going off-patent in India. But will people who need it be able to get it?
Rules determining who gets access to semaglutide in India were written for different bodies with different cardiovascular risks.
GLP-1 Drugs Show Growing Promise for Afib Control
(MedPage Today) — For patients with obesity and atrial fibrillation (Afib), GLP-1 receptor agonist drugs may be the weight loss approach that better addresses their arrhythmia, observational data suggested.
People who came out of catheter ablation…
Hold GLP-1s Before Endoscopy? Clinical Trial Finds Retained Gastric Contents
(MedPage Today) — Patients on GLP-1 or GLP-1/GIP agonists had significant residual gastric volume (RGV) if the medication wasn’t held prior to upper endoscopy unless they were on a clear liquid diet the day before, the OCULUS randomized trial…
Unixell Biotech’s UX-GIP001 gains IND clearance for epilepsy
Shanghai Unixell Biotechnology Co. Ltd. has obtained IND clearance from the FDA for UX-GIP001, its iPSC-derived allogeneic cell therapy for focal epilepsy. A phase I study will evaluate UX-GIP001 in patients with drug-resistant epilepsy.
STAT+: Structure Therapeutics reports significant weight loss from mid-stage GLP-1 pill
An experimental obesity pill from Structure Therapeutics helped patients lose significant weight in a mid-stage trial, with a Phase 3 study in the works.
Structure Therapeutics reports more Phase 2 data for oral GLP-1
Structure Therapeutics has its much-anticipated oral GLP-1 data, and the results look to give the next-generation contender a chance against market incumbents Eli Lilly and Novo Nordisk.
The biotech said Monday …
Martha Stewart’s cardiologist says a simple smoothie add-in is like ‘taking Ozempic’
Martha Stewart says her cardiologist compared beetroot powder to “taking Ozempic” for weight loss. She now adds the supplement daily to her green juice.
What happens when patients stop taking GLP-1 drugs? New study reveals real world insights
As the use of injectable GLP-1 drugs continues to rise, questions persist about what happens after patients stop taking them in real-world settings. A new Cleveland Clinic analysis of nearly 8,000 patients suggests that discontinuing semaglutide and tirzepatide, on average, does not lead to significant weight regain in clinical practice, as many patients later restart the original medication or try an alternative obesity treatment.
‘Mormon Wives’ star weighs just 99 pounds at 5′ 10″, admits GLP-1 addiction
Layla Taylor reveals her eating disorder struggle on “Mormon Wives.” She weighs just 99 pounds at 5’10” and says she’s unable to stop destructive patterns.
Why Ozempic users are actually spending more on high-end chocolate
A new report from Lindt & Sprüngli suggests households using GLP-1 weight-loss medications are driving stronger growth in premium chocolate sales, even as some research shows overall food spending declines.